Vanda Pharmaceuticals Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vanda Pharmaceuticals Inc. - overview
Established
2003
Location
-, DC-DC, US
Primary Industry
Pharmaceuticals
About
Vanda Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for unmet medical needs, focusing on complex medical conditions. Founded in 2003, Vanda Pharmaceuticals is headquartered in Washington, US, and specializes in developing treatments for conditions like sleep disorders and schizophrenia. The company completed its IPO in April 2006, raising USD 57. 5 mn.
Vanda Pharmaceuticals Inc. develops and commercializes innovative biopharmaceutical products, including HETLIOZ® (tasimelteon) for Non-24-Hour Sleep-Wake Disorder, Fanapt® (iloperidone) for schizophrenia, and Ponvory® (ponesimod) for multiple sclerosis. These products address specific biological pathways to improve patient quality of life and are distributed in the US and select international markets. In the most recent year, 2024, Vanda Pharmaceuticals reported revenues of USD 198.
77 mn, while experiencing an EBITDA of USD -34. 525 mn. Vanda Pharmaceuticals plans to leverage its recent funding from the IPO completed in April 2006, where it raised USD 57. 5 mn, to support ongoing product development and potential expansion into new markets.
The company aims to introduce new therapeutic options in regions with limited treatment availability, although specific future product launches or dates have not been disclosed.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.vandapharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Vanda Pharmaceuticals Inc. - timeline of key events
Vanda Pharmaceuticals Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 31,270,000 | 32,727,000 | 33,879,000 | 50,157,000 | 109,925,000 | 146,017,000 | 165,083,000 | 193,118,000 | 227,188,000 | 248,168,000 | 268,682,000 | 254,382,000 | - | - | - |
| % Revenue Growth (YoY) | - | 4.7% | 3.5% | 48.0% | 119.2% | 32.8% | 13.1% | 17.0% | 17.6% | 9.2% | 8.3% | (5.3%) | - | - | - |
| EBITDA (USD) | (7,843,000) | (25,537,000) | (18,318,000) | 23,020,000 | (25,954,000) | (6,641,000) | (14,345,000) | 22,473,000 | 22,603,000 | 30,282,000 | 46,655,000 | 9,062,000 | - | - | - |
| Operating Income (USD) | (10,707,000) | (28,225,000) | (20,400,000) | 20,062,000 | (40,185,000) | (18,571,000) | (16,903,000) | 21,738,000 | 22,810,000 | 27,239,000 | 42,165,000 | 6,329,000 | - | - | - |
| Operating Margin | (34.2%) | (86.2%) | (60.2%) | 40.0% | (36.6%) | (12.7%) | (10.2%) | 11.3% | 10.0% | 11.0% | 15.7% | 2.5% | - | - | - |
| % EBITDA Margin | (25.1%) | (78.0%) | (54.1%) | 45.9% | (23.6%) | (4.5%) | (8.7%) | 11.6% | 9.9% | 12.2% | 17.4% | 3.6% | - | - | - |
| NET Income (USD) | (9,802,000) | (27,664,000) | (20,255,000) | 20,186,000 | (39,865,000) | (18,010,000) | (15,567,000) | 25,208,000 | 115,553,000 | 23,337,000 | 33,152,000 | 6,275,000 | - | - | - |
| % Net Margin | (31.3%) | (84.5%) | (59.8%) | 40.2% | (36.3%) | (12.3%) | (9.4%) | 13.1% | 50.9% | 9.4% | 12.3% | 2.5% | - | - | - |
Vanda Pharmaceuticals Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | Vanda Pharmaceuticals Inc. | - | ||||||||
| Series B | Completed | Vanda Pharmaceuticals Inc. | - |
Displaying 1 - 2 of 2
Vanda Pharmaceuticals Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.